Actuate Therapeutics’ (NASDAQ:ACTU) Quiet Period To Expire on September 23rd

Actuate Therapeutics’ (NASDAQ:ACTU) quiet period is set to expire on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During Actuate Therapeutics’ quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Actuate Therapeutics Stock Performance

Shares of NASDAQ:ACTU opened at $7.31 on Monday. Actuate Therapeutics has a 1 year low of $7.01 and a 1 year high of $10.16. The company has a market cap of $139.69 million and a PE ratio of 48.73.

Insider Buying and Selling at Actuate Therapeutics

In related news, major shareholder Leslie W. Kreis sold 24,999 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $9.00, for a total transaction of $224,991.00. Following the completion of the transaction, the insider now owns 131,248 shares in the company, valued at approximately $1,181,232. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Leslie W. Kreis sold 24,999 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total value of $224,991.00. Following the completion of the transaction, the insider now directly owns 131,248 shares of the company’s stock, valued at approximately $1,181,232. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Todd S. Thomson sold 18,750 shares of Actuate Therapeutics stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $8.00, for a total transaction of $150,000.00. Following the sale, the insider now directly owns 1,184,795 shares in the company, valued at approximately $9,478,360. The disclosure for this sale can be found here. Insiders own 19.90% of the company’s stock.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.